Stock Fundamentals

AI Research Report

Generate a comprehensive financial analysis report powered by AI

RGNX.US Logo

RGNX.US - Current Price

$14.61

Company Information

▼
Company Name
Regenxbio Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US75901B1070
CIK: 0001590877
CUSIP: 75901B107
Currency: USD
Full Time Employees: 353
Phone: 240 552 8181
Website: https://www.regenxbio.com
Fiscal Year End: December
IPO Date: Sep 17, 2015
Description:

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Address:

9804 Medical Center Drive, Rockville, MD, United States, 20850

Directors & Officers

▼
Name Title Year Born
Mr. Curran M. Simpson M.S. President, CEO & Director 1962
Mr. Mitchell Chan M.B.A. Executive VP & CFO 1981
Dr. Olivier Danos Ph.D. Executive VP & Chief Scientific Officer 1958
Mr. Patrick J. Christmas II, J.D. Executive VP & Chief Strategy and Legal Officer 1971
Dr. Stephen Pakola M.D. Executive VP & Chief Medical Officer 1969
Mr. Craig Malzahn Executive VP of Product Development & CTO NA
Ms. Shiva G. Fritsch Chief Communications & People Officer NA
Ms. Sarah Thomas Senior Vice President of Quality NA
Dr. Ram Palanki Pharm.D. Executive VP & Chief Commercial Officer 1976
Dr. Jahannaz Dastgir D.O. Clinical Development Lead NA

Shares Statistics

▼
Shares Outstanding: 50.62M
Shares Float: 41.74M
% Insiders: 764.10%
% Institutions: 8,463.80%
Short % Float: 11.91%

Valuation Metrics

▼
Enterprise Value: $565.70M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

▼
Market Cap: $763.40M
EBITDA: $-139.16M
PEG Ratio: $0.26
Book Value: $3.19
Earnings/Share: $-3.46
Profit Margin: -110.29%
Operating Margin: -176.27%
ROA (TTM): -18.54%
ROE (TTM): -76.88%
Revenue (TTM): $161.32M
Revenue/Share (TTM): $3.14
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 22.90%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

▼

Revenue & Net Income

Operating Expenses

Balance Sheet Overview

Earnings Per Share (EPS)

Earnings History

▼
Date EPS Actual EPS Estimate Difference Surprise %
Dec 31, 2025 0.00 -0.73 N/A 10,000.00%
Sep 30, 2025 -1.20 -1.30 N/A 769.23%
Jun 30, 2025 -1.38 -0.94 N/A -4,680.85%
Mar 31, 2025 0.12 0.49 N/A -7,528.83%
Dec 31, 2024 -1.01 -1.08 N/A 686.09%
Sep 30, 2024 -1.17 -1.12 N/A -446.43%
Jun 30, 2024 -1.05 -1.29 N/A 1,860.47%
Mar 31, 2024 -1.33 -1.26 N/A -555.56%
Dec 31, 2023 -1.43 -1.27 N/A -1,259.84%
Sep 30, 2023 -1.41 -1.52 N/A 723.68%
Jun 30, 2023 -1.66 -1.38 N/A -2,028.99%
Mar 31, 2023 -1.53 -1.54 N/A 64.94%
Dec 31, 2022 -1.38 -1.23 N/A -1,219.51%
Sep 30, 2022 -1.75 -1.46 N/A -1,986.30%
Jun 30, 2022 -1.58 -1.53 N/A -326.80%
Mar 31, 2022 -1.79 -1.32 N/A -3,560.61%
Dec 31, 2021 6.67 4.71 N/A 4,161.36%
Sep 30, 2021 -1.37 -1.08 N/A -2,685.19%
Jun 30, 2021 -1.36 -1.12 N/A -2,142.86%
Mar 31, 2021 -1.20 -1.28 N/A 625.00%
Dec 31, 2020 -1.24 -0.43 N/A -18,837.21%
Sep 30, 2020 0.43 -1.01 N/A 14,257.43%
Jun 30, 2020 -0.91 -0.89 N/A -224.72%
Mar 31, 2020 -1.08 -0.87 N/A -2,413.79%
Dec 31, 2019 -0.72 -0.44 N/A -6,363.64%
Sep 30, 2019 -0.94 -0.71 N/A -3,239.44%
Jun 30, 2019 -0.04 -0.61 N/A 9,344.26%
Mar 31, 2019 -0.89 -0.86 N/A -348.84%
Dec 31, 2018 0.11 -0.34 N/A 13,235.29%
Sep 30, 2018 -0.56 -0.44 N/A -2,727.27%
Jun 30, 2018 0.30 1.23 N/A -7,560.98%
Mar 31, 2018 3.04 1.00 N/A 20,400.00%
Dec 31, 2017 -0.51 -0.82 N/A 3,780.49%
Sep 30, 2017 -0.67 -0.72 N/A 694.44%
Jun 30, 2017 -0.47 -0.75 N/A 3,733.33%
Mar 31, 2017 -0.82 -0.76 N/A -789.47%
Dec 31, 2016 -0.74 -0.75 N/A 133.33%
Sep 30, 2016 -0.69 -0.66 N/A -454.55%
Jun 30, 2016 -0.55 -0.53 N/A -377.36%
Mar 31, 2016 -0.41 -0.40 N/A -250.00%
Dec 31, 2015 -0.20 -0.34 N/A 4,117.65%
Sep 30, 2015 -1.52 N/A N/A N/A

Balance Sheet (Yearly)

▼
Date Cash Total Debt Total Assets Total Liabilities Total Equity
2024-12-31 $57.53M $N/A $465.99M $206.34M $259.65M
2023-12-31 $34.52M $N/A $573.97M $262.23M $311.74M
2022-12-31 $96.95M $N/A $833.27M $317.07M $516.20M
2021-12-31 $345.21M $N/A $1.11B $349.61M $764.30M
2020-12-31 $338.43M $N/A $708.16M $330.41M $377.75M
2019-12-31 $69.51M $N/A $497.91M $47.71M $450.20M
2018-12-31 $75.56M $N/A $543.81M $34.97M $508.85M
2017-12-31 $46.66M $N/A $198.68M $15.65M $183.03M
2016-12-31 $24.84M $N/A $172.73M $11.00M $161.74M
2015-12-31 $54.12M $N/A $221.38M $4.57M $216.81M
2014-12-31 $1.12M $N/A $3.49M $9.19M $-5.70M
2013-12-31 $1.12M $N/A $2.51M $4.65M $-2.14M

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Oct 09, 2025 N/A N/A N/A N/A N/A N/A
Sep 29, 2025 N/A N/A N/A N/A N/A N/A
Sep 10, 2025 N/A N/A N/A N/A N/A N/A
May 12, 2025 N/A N/A N/A N/A N/A N/A

Watchlist

0

No stocks in watchlist